We are live on ! Find out more

Tyra Biosciences

TYRA

Market cap $1.5B

25.07 USD

+3.04

13.8%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

25.48

+0.41

1.64%

1 day

13.8%

5 days

-10.3%

1 month

-0.87%

3 months

-12.19%

6 months

-32.26%

Year to date

-6.42%

1 year

103.66%

5 years

-3.58%

10 years

-3.58%

About: Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Employees: 87

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 66.7%

Negative 25%

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Why Is Tyra Biosciences Stock Sinking Wednesday?

Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.

Why Is Tyra Biosciences Stock Sinking Wednesday?

Investors Business Daily

Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.

Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA's planned registrational adjuvant development strategy.

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference: Cantor Global Healthcare Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ETLocation: New York, NY A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near-term binary risk and opportunity for the company. Company's SNAP platform enables selective FGFR3 targeting, aiming to address efficacy and tolerability gaps left by pan-FGFR inhibitors.

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

See News Rankings

Price charts implemented using Lightweight Charts™